Medicina interna II Consenso Venezolano sobre Enfermedad Tromboembólica (II): Patología Venosa
Referencias I
Davis P. Venous thromboembolism prevention- an update. J Orthopedic Nursing. 2004;8:50-56.
Tamariz L, Eng J, Segal J. Usefulness of Clinical Prediction rules for the Diagnosis of Venous Thromboembolism: A Systematic Review. Am J Med. 2004;117:676-684.
Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous tromboembolism. Chest. 2001;119:132S-175S.
Freedman KB, Brookenthal KR, Fitzgerald RH, et al. A meta-analysis of thromboembolic prophylaxis following elective total hip arthroplasty. J Bone Joint Surg Am. 2000;82:929-938.
Amarigiri SV, Lees TA. Elastic compression stockings for prevention of deep vein thrombosis. (Cochrane Review). In: The Cochrane Library, Issue 3, 2000. Oxford: Update Sofrware.
Hull RD, Raskob GE, Gent M, et al. Effectiveness of intermittent pneumatic leg compression for preventing deep vein thrombosis after total hip replacement. JAMA .1990;263:2313-2317.
Blanchard J, Meuwly JY, Leyvraz PF, et al. Prevention of deep-vein thrombosis after total knee replacement. Randomized comparison between a low-molecular-weight heparin (nadroparin) and mechanical prophylaxis with a foot-pump system. J Bone Joint Surg Br. 1999;81:654-659.
Comerota AJ, Katz ML, White JV. Why does prophylaxis with external pneumatic compression for deep vein thrombosis fail? Am J Surg. 1992; 164:265-268.
Handoll HHG, Farrar MJ, McBirnie J, Tytherleigh-Strong G et al. Heparin, low molecular weight heparin and physical methods for preventing deep vein thrombosis and pulmonary embolism following surgery for hip fractures (Cochrane Review). In: The Cochrane Library, Issue 3, 2000. Oxford: Update Sofrware.
Prothero SR, Parkes JC, Stinchfield FE. Complications after low-back fusion in 1000 patients: a comparison of two series one decade apart. J Bone Joint Surg Am 1966; 48:57-69.
Heit JA, O'Fallon WM, Petterson TM, et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med 2002; 162:1245-1248.
Cornwell EE, Chang D, Velmahos G, et al. Compliance with sequential compression device prophylaxis in at-risk trauma patients: a prospective analysis. Am Surg 2002;68:470-473.
Hirsh J, Canada H, Raschke R eta al. Heparin: Mecanism of Action, Pharmacokinetics, Dosing Considerations, Monitoring, Efficacy, and Safety. Chest 1995;108(4):258S-275S.
Fareed J, Hoppensteadt D, Walenga J, et al. Phatmacodynamic anbd pharmacokinetic properties of enoxaparin. Implications for cl_nical practice. Clin Pharmacokinet 2003; 42(12):1043-1057.
Jhonson P, Smith M. Low molecular weight heparin use in special populations. Pharmacology up date. 2004; 27(12):1245-1248.
Bratt G, Tornebohm E, Widlund L, et al. Low molecular weight heparin (KABI 2165, FRAGMIN): pharmacokinetics after intravenous and subcutaneous administration in human volunteers. Thromb Res 1986; 42:613-620.
Bara L, Samama MM. Pharmacokinetics of low molecular weight heparins. Acta Chir Scand 1988; 543:65-72.
Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997;337:688-698.
Hirsh J, Canada H, Dalen J, et al. Oral Anticoagulants: Mechanism of Action, Clinical Effectiveness, and Optomal Therapeutic Range. Chest 1995; 108(4):231S-246S.
Bauer KA. Fondaparinux: a new synthetic and selective inhibitor of Factor Xa. Best Practice & Research Clinical Haematology 2004;17(1):89-104.
Carlsson, SC, Mattsson C, Ericsson UG, et al. A review of the effects of the oral direct thrombin inhbitor ximelagatran on coagulation assays. Trombosis Research 2005;115:9-18.
Travel by air: Health Considerations, Cap 2 en: International Travel and Health. Situations as on I January 2005.
Grupo de Expertos en Medicina del Viajero. Organizaci_n Mundial de la Salud:12-24.
Belcaro G, Geroulakos G, Nicolaides AN, et al. Venous thromboembolism from air travel: the LONFLIT Study. Angiology 2001;52:369-374.
Gallus AS, Goghlan DC. Travel and venous thrombosis. Curr Opin Pulm Med 2002;8:372-378.
Ten Wolde M, Kraaijenhagen RA, Schiereck J, et al. Travel and the risk of symptomatic venous thromboembolism. Thromb Haemost 2003;89:499-505.
Alikhan R, Cohen A, Combe S, et al. Risk factor for venous thromboembolism in hospitalized patients with acute medical illnes. An_lisis of MEDENOX study. Arch Intern Med 2004; 164(10):963-968.
Belch JJ, Lowe GDO, Ward AG, et al. Prevention of deep vein thrombosis in medical patients by low-dose heparin. Scott Med J 1981;26:115-117.
Haas SK. Venous thromboembolic risk and its prevention in hospitalized medical patients. Semin Thromb Haemost 2002;28:577-583.
Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med 1999;341:793-800.
Oger E, Bressollette L, Nonent M, et al. High prevalence of asymptomatic deep vein thrombosis on admission in a medical unit among elderly patients: the TADEUS Project. Thromb Haemost 2002;88:592-597.
Leizorovicz A, Cohen AT, Turpie AGG, et al. A randomized placebo controlled trial of dalteparin for the prevention of venous thromboembolism in 3706 acutely ill medical patients: the PREVENT medical thromboprophylaxis study [abstract]. J Thromb Haemost 2003; 1(suppl):OC396.
Bergmann JF, Neuhart E. A multicenter randomized double-blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in-patients bedridden for an acute medical illness. Thromb Haemost 1996;76:529-534.
Harenberg J, Roebruck P, Heene DL, et al. Subcutaneous low-molecular-weight heparin versus standard heparin and the prevention of thromboembolism in medical inpatients. Haemostasis 1996; 26:127-139.
Lechler E, Schramm W, Flosbach CW, et al. The venous thrombotic risk in non-surgical patients: epidemiological data and efficacy/safety profile of a low-molecular-weight heparin (enoxaparin). Haemostasis 1996; 26(suppl):49-56.
Kleber FX, Witt C, Vogel G, et al. Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. Am Heart J 2003;145:614-621.
Alikhan R, Cohen AT. A safety analysis of thromboprophylaxis in acute medical illness. Thromb Haemost 2003;89:590-591.
Gallus AS, Hirsh J, Tuttle RJ, et al. Small subcutaneous doses of heparin in prevention of venous thrombosis. N Engl J Med 1973;288:545-551.
Cade JF. High risk of the critically ill for venous thromboembolism. Crit Care Med 1982;10:448-450.
Anne JA, Wilburd K, Burton E. Effect of patient weight on the anticoagulation response to adjusted therapeutic dosage of low molwcular weight heparin for the treatment of venous thromboembolism. Haemostasia 2001;31:42-48
Dahan R, Houlbert D, Caulin C, et al. Prevention of deep vein thrombosis in elderly medical in-patients by a low molecular weight heparin: a randomized double-blind trial. Haemostasis 1986;16:159-164.
Haas SK. Venous Thromboembolic Risk and Its Prevention in Hospitalized Medical Patients. Semin Thromb Hemost 2000;28(6):577-583.
Nicolaides AN, Breddin HK, Fareed J, et al. Prevention of venous thromboembolism. International Consensus Statement. Guidelines compiled in accordance with the scientific evidence. Int Angiol 2001;20:1-37.
Bick RL. Proficient and cost-effective approaches for the prevention and treatment of venous thrombosis and thromboembolism. Drugs 2000;60:575-595
Geerts WH, Selby R. Prevention of venous thromboembolism in the ICU. Chest 2003;124(suppl):357S-363S.
Baglin TP, White K, Charles A. Fatal pulmonary embolism in hospitalized medical patients. J Clin Pathol 1997;50:609-610.
Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy: III. Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. BMJ 1994;308:235-246.
Lotke PA, Palevsky H, Keenan AM, et al. Aspirin and warfarin for thromboembolic disease after total joint arthroplasty. Clin Orthop 1996; 324:251-258.
Pulmonary Embolism Prevention (PEP) Trial Collaborative Group. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) Trial. Lancet 2000;355:1295-1302.
Geerts WH, Pineo GF, Heit JA, et al. Prevention of Venous Thrombembolism. Chest 2004;126: 338S-400S.
Consenso Venezolano de Enfermedad Tromboembólica Venosa. Reunión de Margarita - Venezuela. Noviembre 2000.
Moser G, Krahenbuhl B, Barroussel R, et al. Mechanical versus pharmacologic prevention of deep venous thrombosis. Surg Gynecol Obstet 1981;152:448-450.
Nicolaides AN, Miles C, Hoare M, et al. Intermittent sequential pneumatic compression of the legs and thromboembolism-deterrent stockings in the prevention of postoperative deep venous thrombosis. Surgery 1983;94:21-25.
Scurr JH, Coleridge-Smith PD, Hasty JH. Regimen for improved effectiveness of intermittent pneumatic compression in deep venous thrombosis prophylaxis. Surgery 1987;102:816-820.
Butson AR. Intermittent pneumatic calf compression for prevention of deep venous thrombosis in general abdominal surgery. Am J Surg 1981;142:525-527
Cipolle MD, Wojcik R, Seislove E, et al. The role of surveillance duplex scanning in preventing venous thromboembolism in trauma patients. J Trauma 2002: 52:453-462.
Van Ooijen B. Subcutaneous heparin and postoperative wound hematomas: a prospective, double-blind, randomized study. Arch Surg 1986;121:937-940.
Clagett GP, Reisch JS. Prevention of venous thromboembolism in general surgical patients: results of meta-analysis. Ann Surg 1988;208:227-240.
Kakkar VV, Murray WJ. Efficacy and safety of low-molecular-weight heparin (CY216) in preventing postoperative venous thrombo-embolism: a co-operative study. Br J Surg 1985;72:786-791.
Egger B, Schmid SW, Naef M, et al. Efficacy and safety of weight-adapted nadroparin calcium vs. heparin sodium in prevention of clinically evident thromboembolic complications in 1,190 general surgical patients. Dig Surg 2000;17:602-609.
McLeod RS, Geerts WH, Sniderman KW, et al. Subcutaneous heparin versus low-molecular-weight heparin as thromboprophylaxis in patients undergoing colorectal surgery: results of the Canadian Colorectal DVT Prophylaxis Trial: a randomized, double-blind trial. Ann Surg 2001;233:438-444.
Haas S, Flosbach CW. Prevention of postoperative thromboembolism with enoxaparin in general surgery: a German multicenter trial. Semin Thromb Haemost 1993;19(suppl):164-173.
Lausen I, Jensen R, Jorgensen LN, et al. Incidence and prevention of deep venous thrombosis occurring late after general surgery: randomised controlled study of prolonged thromboprophylaxis. Eur J Surg 1998;164:657-663.
Bergqvist D, Burmark US, Frisell J, et al. Low molecular weight heparin once daily compared with conventional low-dose heparin twice daily: a prospective double-blind multicentre trial on prevention of postoperative thrombosis. Br J Surg 1986;73:204-208.
Caen JP. A randomized double-blind study between a low molecular weight heparin Kabi 2165 and standard heparin in the prevention of deep vein thrombosis in general surgery: a French multicenter trial. Thromb Haemost 1988;59:216-220.
European Fraxiparin Study (EFS) Group. Comparison of a low molecular weight heparin and unfractionated heparin for the prevention of deep vein thrombosis in patients undergoing abdominal surgery. Br J Surg 1988; 75:1058-1063.
Samama MM, Bernard P, Bonnardot JP, et al. Low molecular weight heparin compared with unfractionated heparin in prevention of postoperative thrombosis. Br J Surg 1988;75:128-131.
Hartl P, Brucke P, Dienstl E, et al. Prophylaxis of thromboembolism in general surgery: comparison between standard heparin and Fragmin. Thromb Res 1990;57:577-584.
Liezorovicz A, Picolet H, Peyrieux JC, et al. Prevention of perioperative deep vein thrombosis in general surgery: a multicentre double blind study comparing two doses of Logiparin and standard heparin. Br J Surg 1991;78:412-416.
Boneu B. An international multicentre study: clivarin in the prevention of venous thromboembolism in patients undergoing general surgery; report of the International Clivarin Assessment Group. Blood Coagul Fibrinolysis 1993; 4(suppl):S21-S22.
Gazzaniga GM, Angelini G, Pastorino G, et al. Enoxaparin in the prevention of deep venous thrombosis after major surgery: multicentric study. Int Surg 1993; 78:271-275.
Second Thromboembolic Risk Factors (THRiFT II) Consensus Group. Risk of and prophylaxis for venous thromboembolism in hospital patients. Phlebology 1998;13:87-97.
Sullivan SD, Kahn SR, Davidson BL, et al. Measuring the outcomes and pharmacoeconomic consequences of venous thromboembolism prophylaxis in major orthopaedic surgery. Pharmacoeconomics 2003;21:477-496.
Anderson FA, Wheeler HB, Goldberg RJ, et al. The prevalence of risk factors for venous thromboembolism among hospital patients. Arch Intern Med 1992; 152:1660-1664.
Hedlund PO, Blomback M. The effects of low-dose heparin treatment on patients undergoing transvesical prostatectomy. Urol Res 1981;9:147-152.
Sleight MW. The effect of prophylactic subcutaneous heparin on blood loss during and after transurethral prostatectomy. Br J Urol 1982;54:164-165.
Coe NP, Collins RE, Klein LA, et al. Prevention of deep vein thrombosis in urological patients: a controlled, randomized trial of low-dose heparin and external pneumatic compression boots. Surgery 1978;83:230-234.
Cisek LJ, Walsh PC. Thromboembolic complications following radical retropubic prostatectomy: influence of external sequential pneumatic compression devices. Urology 1993;42:406-408.
Donat R, Mancey-Jones B. Incidence of thromboembolism after transurethral resection of the prostate (TURP): a study on TED stocking prophylaxis and literature review. Scand J Urol Nephrol 2002;36:119-123.
Bergqvist D, Bergentz SE, Bornmyr S, et al. Deep vein thrombosis after renal transplantation: a prospective analysis of frequency and risk factors. Eur Surg Res 1985;17:69-74.
Allen RD, Michie CA, Murie JA, et al. Deep venous thrombosis after renal transplantation. Surg Gynecol Obstet 1987;164:137-142.
Angermeier KW, Jordan GH. Complications of the exaggerated lithotomy position: a review of 177 cases. J Urol 1994;151:866-868.
Soderdahl DW, Henderson SR, Hansberry KL. A comparison of intermittent pneumatic compression of the calf and whole leg in preventing deep venous thrombosis in urological surgery. J Urol 1997;157:1774-1776.
White RH, Zhou H, Romano PS. Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures. Thromb Haemost 2003;90:446-455.
Bigg SW, Catalona WJ. Prophylactic mini-dose heparin in patients undergoing radical retropubic prostatectomy: a prospective trial. Urology 1992; 39:309-313.
Sebeseri O, Kummer H, Zingg E. Controlled prevention of post-operative thrombosis in urological diseases with depot heparin. Eur Urol 1975;1:229-230.
Ssch_nemann H. Munger H, Brower S, et al. Methodology for guideline development for the Seventh American College of Chest Physicians conference on antithrommbotic and thrombolytic therapy. Chest 2004;126:174S-178S.
Clarke-Pearson DL, Dodge RK, Synan L, et al. Venous thromboembolism prophylaxis: petients at high risk to fail intermittent pneumatic compression. Obstet Gynecol. 2003;101:157-163
Baykal C, Al A, Demirtas E, et al. Comparison of enoxaparin and st_ndar heparin in gynaecologic oncolgic surgery: a randomised prospective double-blind study. Eur J Gynaecol Oncol 2001; 22:127-130
ACOG Practice Bulletin. Prevention of deep vein thrombosis and pulmonary embolism. Obstet Gynecol 2000; 96(suppl):1-10
Maxwell GL, Synan I, Dodge R, et al. Pneumatic compression versus low molecular weight heparin in gynecologic oncology surgery: a randomized trial. Obstet Gynecol 2001;98:989-995.
Clarke-Pearson DL, Synan IS, Dodge R, et al. A randomized trial of low-dose heparin and intermittent pneumatic calf compression for the prevention of deep venous thrombosis after gynecologic oncology surgery. Am J Obstet Gynecol 1993;168:1146-1154.
Urlep-Salinovic V, Jelatancev B, Gorisek B. Low doses of heparin and heparin dihydergot in post-operative thromboprophylaxis in gynaecological patients. Thromb Haemost 1994;72:16-20.
Ward B, Pradhan S. Comparison of low molecular weight heparin (Fragmin) with sodium heparin for prophylaxis against postoperative thrombosis in women undergoing major gynaecological surgery. Aust N Z J Obstet Gynaecol 1998; 38:91-92.
Dubuc-Lissoir J, Ehlen T, Heywood M, et al. Prevention and treatment of thromboembolic disease in gynaecological surgery. J Soc Obstet Gynaecol Can 1999; 21:1087-1094.
Heilmann L, von Tempelhoff GF, Kirkpatrick C, et al. Comparison of unfractionated versus low molecular weight heparin for deep vein thrombosis prophylaxis during breast and pelvic cancer surgery: efficacy, safety, and follow-up. Clin Appl Thromb Hemost 1998;4:268-273.
Clarke-Pearson DL, Synam IS, Coleman RE, et al. The natural history of postoperative venous thromboemboli in gynecologic oncology: a prospective study of 382 patients. Am J Obstet Gynecol 1984;148:1051-1054.
Clarke-Pearson DL, Creasman WT, Coleman RE, et al. Perioperative external pneumatic calf compression as thromboembolism prophylaxis in gynecologic oncology: report of a randomized controlled trial. Obstet Gynecol 1984;18:226-232.
Clarke-Pearson DL, Synan IS, Hinshaw WM, et al. Prevention of postoperative venous thromboembolism by external pneumatic calf compression in patients with gynecologic malignancy. Obstet Gynecol 1984; 63:92-98.
Clarke-Pearson DL, Coleman RE, Synan IS, et al. Venous thromboembolism prophylaxis in gynecologic oncology: a prospective, controlled trial of low-dose heparin. Am J Obstet Gynecol 1983;145:606-613.
Clarke-Pearson DL, DeLong E, Synam IS, et al. A controlled trial of two low-dose heparin regimens for the prevention of postoperative dep vein thrombosis. Obstet Gynecol 1990;75:684-689.
Fricker JP, Vergnes Y, Schach R, et al. Low dose heparin versus low molecular weight heparin (Kabi 2165, Fragmin) in the prophylaxis of thromboembolic complications of abdominal oncological surgery. Eur J Clin Invest 1988;18:561-567.
Haas S, Flosbach CW. Antithromboembolic efficacy and safety of enoxaparin in general surgery. Eur J Surg 1994; 571(suppl):37-43.
ENOXACAN Study Group. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. Br J Surg 1997;84:1099-1103.
Kakkar VV, Boeckl O, Boneu B, et al. Efficacy and safety of a low-molecular-weight heparin and standard unfractionated heparin for prophylaxis of postoperative venous thromboembolism: European multicenter trial. World J Surg 1997;21:2-8.
Haas SK, Wolf H, Encke A, et al. Prevention of fatal postoperative pulmonary embolism by low molecular weight heparin: a double blind comparison of certoparin and unfractionated heparin [abstract]. Thromb Haemost 1999; 82(suppl):491.
Bounameaux H, Huber O, Khabiri E, et al. Unexpectedly high rate of phlebographic deep venous thrombosis following elective general abdominal surgery among patients given prophylaxis with low-molecular-weight heparin. Arch Surg 1993;128:326-328.
Kakkar VV, Kakkar S, Sanderson RM, et al. Efficacy and safety of two regimens of low molecular weight heparin fragment (Fragmin) in preventing postoperative venous thrombolism. Haemostasis 1986;16(suppl):19-24.
Bjerkeset O, Larsen S, Reiertsen O. Evaluation of enoxaparin given before and after operation to prevent venous thromboembolism during digestive surgery: play-the-winner designed study. World J Surg 1997;21:584-588.
Bounameaux H, Didier D, Polat O, et al. Antithrombotic prophylaxis in patients undergoing laparoscopic cholecystectomy. Thromb Res 1997;86:271-273.
Patel MI, Hardman DT, Nicholls D, et al. The incidence of deep venous thrombosis after laparoscopic cholecystectomy. Med J Aust 1996;164:652-656.
Lord RV, Ling JJ, Hugh TB, et al. Incidence of deep vein thrombosis after laparoscopic vs minilaparotomy cholecystectomy. Arch Surg 1998;133:967-973.
Zacharoulis D, Kakkar AK. Venous thromboembolism in laparoscopic surgery. Curr Opin Pulm Med 2003;9:356-361.
Tvedskov TF, Rasmussen MS, Willie-Jorgensen P. Survey of the use of thromboprophylaxis in laparoscopic surgery in Denmark. Br J Surg 2001; 88:1413-1416.
Blake AM, Toker SI, Dunn E. Deep venous thrombosisprophylaxis is not indicated for laparosocopic cholecystectomy. J Soc Laparosc Surg 2001; 5:215-219.
Catheline JM, Turner R, Gaillard JL, et al. Thromboembolism in laparoscopic surgery: risk factors and preventive measures. Surg Laparosc Endosc Percutan Tech 1999;9:135-139.
Lindberg F, Rasmussen I, Siegbahn A, et al. Coagulation activation after laparoscopic cholecystectomy in spite of thromboembolism prophylaxis. Surg Endosc 2000;14:858-861.
Bergqvist D, Lowe G. Venous thromboembolism in patients undergoing laparoscopic and arthroscopic surgery and in leg casts. Arch Intern Med 2002; 162:2173-2176.
Scholten DJ, Hoedema RM, Scholten S.E. A comparison of two different prophylactic dose regimens of low molecular weigth heparin un bariatric surgery. Obes Surg 2002;12:19-24.
Koppenhagen K, Adolf J, Matthes M, et al. Low molecular weight heparin and prevention of postoperative thrombosis in abdominal surgery. Thromb Haemost 1992;67:627-630.
Sanderink GJ, Le Liboux A, Jariwala N, Harding N, Ozoux ML, Shu... U, Montay G, Boutouyrie B, Miro A. The pharmacokinetics and pharmacodynamics of enoxapari.... obese volunteers. Clin Pharmacol 2002:72(3):308-318.
Wait M, Hunt JL, Purdue GF. Duplex scanning of central vascular access sites in burn patients. Ann Surg 1990;211:499-503.
Gnoyski JM, Keen ME, Gamelli RL, et al. Deep venous thrombosis and the association with burns involving the lower extremities [abstract]. Arch Phys Med Rehabil 1994;75:1045129.
Harrington DT, Burke B, Bird P, et al. Thermally injured patients are at significant risk of thromboembolic complications [abstract]. J Burn Care Rehabil 1999;20:S178.
Wahl WL, Brandt MM, Ahrns KS, et al. Venous thrombosis incidence in burn patients preliminary results of a prospective study. J Burn Care Rehabil 2002;23:97-102.
Raskob GE, Hirsh J. Controversies in timing of the first dose of anticoagulant prophylaxis against venous thromboembolism after major orthopedic surgery. Chest 2003;124(suppl):379S-385S.
Hull RD, Pineo GF, Stein PD, et al. Timing of initial administration of low-molecular-weight heparin prophylaxis against deep vein thrombosis in patients following elective hip arthroplasty: a systematic review. Arch Intern Med 2001;161:1952-1960.
Kearon C. Duration of venous thromboembolism prophylaxis after surgery. Chest 2003;124(suppl):386S-392S.
Eriksson BI, Lassen MR. The PENTasaccharide in HIp-FRActure Surgery Plus (PENTHIFRA Plus) Invetigators. Duration of prophylaxis against venous thromboembolismwith fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study. Arch Intern Med 2003; 163:1337-1342.
132. Agnelli G, Bergqvist D, Cohen A, et al. Randomized doubleblind study to compare the efficacy and safety of postoperative fondaparinux (Arixtra) and preoperative dalteparin in the prevention of venous thromboembolism after high-risk abdominal surgery: the PEGASUS Study [abstract]. Blood 2003; 102:15a.
Lassen MR, Borris LC, Christiansen HM, et al. Prevention of thromboembolism in 190 hip arthroplasties: comparison of LMW heparin and placebo. Acta Orthop Scand 1991; 62:33-38
Warwick D, Bannister GC, Glew D, et al. Perioperative low-molecular-weight heparin: is it effective and safe? J Bone Joint Surg Br 1995;77:715-719.
Barnes RW, Brand RA, Clarke W, et al. Efficacy of Gradedcompression antiembolism stockings in patients undergoing total hip arthroplasty. Clin Orthop 1978;132:61-67.
Gallus A, Raman K, Darby T. Venous thrombosis after elective hip replacement-the influence of preventive intermittent calf compression and of surgical technique. Br J Surg 1983;70:17-19.
Paiement G, Wessinger SJ, Waltman AC, et al. Low-dose warfarin versus external pneumatic compression for prophylaxis against venous thromboembolism following total hip replacement. J Arthroplasty 1987;2:23-26.
Bailey JP, Kruger MP, Solano FX, et al. Prospective randomized trial of sequential compression devices vs low-dose warfarin for deep venous thrombosis prophylaxis in total hip arthroplasty. J Arthroplasty 1991; 6(suppl):S29-S35.
Kaempffe FA, Lifeso RM, Meinking C. Intermittent pneumatic compression versus Coumadin: prevention of deep vein thrombosis in low-extremity total joint arthroplasty. Clin Orthop 1991;269:89-97.
Francis CW, Pellegrini VD, Marder VJ, et al. Comparison of warfarin and external pneumatic compression in prevention of venous thrombosis after total hip replacement. JAMA 1992;267:2911-2915.
Norgren L, Austrell C, Brummer R, et al. Low incidence of deep vein thrombosis after total hip replacement: an interim analysis of patients on low molecular weight heparin vs sequential gradient compression prophylaxis. Int Angiol 1996;15(suppl):11-14.
Mesko JW, Brand RA, Iorio RA, et al. Venous thromboembolic disease management patterns in total hip arthroplasty and total knee arthroplasty patients: a survey of the AAHKS membership. J Arthroplasty 2001; 16:679-688
RD Heparin Arthroplasty Group. RD heparin compared with warfarin for prevention of venous thromboembolic disease following total hip or knee arthroplasty. J Bone Joint Surg Am 1994;76:1174-1185.
Caprini JA, Arcelus JI, Motykie G, et al. The influence of oral anticoagulation therapy on deep vein thrombosis rates four weeks after total hip replacement. J Vasc Surg 1999;30:813-820.
German Hip Arthroplasty Trial Group (GHAT). Prevention of deep vein thrombosis with low molecular-weight heparin in patients undergoing total hip replacement: a randomized trial. Arch Orthop Trauma Surg 1992;111:110-120.
Hull R, Raskob GE, Pineo G, et al. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N Engl J Med 1993;329:1370-1376
Hull RD, Pineo GF, Francis C, et al. Low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery vs warfarin in hip arthroplasty patients: a doubleblind, randomized comparison. Arch Intern Med 2000; 160:2199-2207.
Leyvraz PF, Richard J, Bachmann F, et al. Adjusted versus fixed-dose subcutaneous heparin in the prevention of deepvein thrombosis after total hip replacement. N Engl J Med 1983;309:954-958.
Planes A, Vochelle N, Mazas F, et al. Prevention of postoperative venous thrombosis: a randomized trial comparing unfractionated heparin with low molecular weight heparin in patients undergoing total hip replacement. Thromb Haemost 1988;60:407-410.
Kakkar VV, Howes J, Sharma V, et al. A comparative, double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of postoperative venous thromboembolism. Thromb Haemost 2000; 83:523-529.
Colwell CW, Spiro TE, Trowbridge AA, et al. Use of enoxaparin, a low-molecular-weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement: a clinical trial comparing efficacy and safety. J Bone Joint Surg Am 1994;76:3-14.
Amstutz HC, Friscia DA, Dorey F, et al. Warfarin prophylaxis to prevent mortality from pulmonary embolism after total hip replacement. J Bone Joint Surg Am 1989; 71:321-326
Paiement GD, Wessinger SJ, Hughes R, et al. Routine use of adjusted low-dose warfarin to prevent venous thromboembolism after total hip replacement. J Bone Joint Surg Am 1993;75:893-898.
Lassen MR, Bauer KA, Eriksson BI, et al. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thrombeombolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet 2002; 359:1715-1720
Turpie AGG, Bauer KA, Eriksson BI, et al. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet 2002;359:1721-1726.
Eriksson BI, Arfwidsson AC, Frison L, et al. A dose ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prevention of thromboembolism after hip or knee replacement: METHRO I. Thromb Haemost 2002;87:231-237.
Eriksson BI, Bergqvist D, Kalebo P, et al. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. Lancet 2002; 360:1441-1447.
Eriksson BI, Agnelli G, Cohen AT, et al. The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or total knee replacement: the EXPRESS Study. J Thromb Haemost 2003; 1:2490-2496
Eriksson BI, Agnelli G, Cohen AT, et al. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or total knee replacement: the METHRO III study. Thromb Haemost 2003;89:288-296.
Colwell CW, Berkowitz SD, Davidson BL, et al. Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement: a randomized, double-blind study. J Thromb Haemost 2003;2003:2119-2130.
Navarro-Quilis A, Castellet E, Rocha E, et al. Efficacy and safety of bemiparin compared with enoxaparin in the prevention of venous thromboembolism after total knee arthroplasty: a randomized, double-blind clinical trial. J Thromb Haemost 2003; 1:425-432
Howard AW, Aaron SD. Low molecular weight heparin decreases proximal and distal deep venous thrombosis folowing total knee arthroplasty: a meta-analysis of randomized trials. Thromb Haemost 1998;79:902-906.
Brookenthal KR, Freedman KB, Lotke PA, et al. A metaanalysis of thromboembolic prophylaxis in total knee arthroplasty. J Arthroplasty 2001; 16:293-300.
Heit JA, Berkowitz SD, Bona R, et al. Efficacy and safety of low molecular weight heparin (ardeparin sodium) compared to warfarin for the prevention of venous thromboembolism after total knee replacement surgery: a doube-blind, doseranging study. Thromb Haemost 1997;77:32-38.
Leclerc JR, Geerts WH, Desjardins L, et al. Prevention of venous thromboembolism after knee arthroplasty: a randomized, double-blind trial comparing enoxaparin with warfarin. Ann Intern Med 1996;124:619-626.
Fitzgerald RH, Spiro TE, Trowbridge AA, et al. Prevention of venous thromboembolic disease following primary total knee arthroplasty: a randomized, multicenter, open-label, parallel-group comparison of enoxaparin and warfarin. J Bone Joint Surg Am 2001;83:900-906.
Turpie AGG, Bauer KA, Eriksson BI, et al. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med 2002; 162:1833-1840.
Bauer KA, Eriksson BI, Lassen MR, et al. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med 2001;345:1305-1310.
Rader CP, Kramer C, Konig A, et al. Low-molecular-weight heparin and partial thromboplastin time-adjusted unfractionated heparin in thromboprophylaxis after total knee and total hip arthroplasty. J Arthroplasty 1998; 13:180-185.
Colwell CW, Spiro TE, Trowbridge AA, et al. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep venous thrombosis after elective knee arthroplasty. Clin Orthop 1995;321:19-27.
Fauno P, Suomalainen O, Rehnberg V, et al. Prophylaxis for the prevention of venous thromboembolism after total knee arthroplasty: a comparison between unfractionated and lowmolecular-weight heparin. J Bone Joint Surg Am 1994;76:1814-1818.
Hoppener MR, Ettema HB, Kraaijenhagen RA, et al. Day-care or short-stay surgery and venous thromboembolism. J Thromb Haemost 2003;1:863-865.
Small NC. Complications in arthroscopic surgery performed by experienced arthroscopists. Arthroscopy 1988;4:215-221.
Bamford DJ, Paul AS, Noble J, et al. Avoidable complications of arthroscopic surgery. J R Coll Surg Edinb 1993;38:92-95.
Demers C, Marcoux S, Ginsberg JS, et al. Incidence of venographically proved deep vein thrombosis after knee arthroscopy. Arch Intern Med 1998; 158:47-50.
Eriksson BI, Bauer KA, Lassen MR, et al. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med 2001;345:1298-1304.
Jorgensen PS, Strandberg C, Willie-Jorgensen P, et al. Early preoperative thromboprophylaxis with Klexane in hip fracture surgery: a placebo-controlled study. Clin Appl Thromb Hemost 1998;4:140-142.
Monreal M, Lafoz E, Navarro A, et al. A prospective double-blind trial of a low molecular weight heparin once daily compared with conventional low-dose heparin three times daily to prevent pulmonary embolism and venous thrombosis in patients with hip fracture. J Trauma 1989;29:873-875.
Barsotti J, Gruel Y, Rosset P, et al. Comparative doubleblind study of two dosage regimens low-molecular weight heparin in elderly patients with a fracture of the neck of the femur. J Orthop Trauma 1990;4:371-375.
TIFDED Study Group. Thromboprophylaxis in hip fracture surgery: a pilot study comparing danaparoid, enoxaparin and dalteparin. Haemostasis 1999; 29:310-317.
Hefley WF, Nelson CL, Puskarich-May CL. Effect of delayed admission to the hospital on the preoperative prevalence of deep-vein thrombosis associated with fractures about the hip. J Bone Joint Surg Am 1996;78:581-583.
Zahn HR, Skinner JA, Porteous MJ. The preoperative prevalence of deep vein thrombosis in patients with femoral neck fractures and delayed operation. Injury 1999;30:605-607.
Powers PJ, Gent M, Jay RM, et al. A randomized trial of less intense postoperative warfarin or aspirin therapy in the prevention of venous thromboembolism after surgery for fractured hip. Arch Intern Med 1989; 149:771-774.
Borgstrom S, Greitz T, van der Linden W, et al. Anticoagulant prophylaxis of venous thrombosis in patients with fractured neck of the femur: a controlled clinical trial using venous phlebography. Acta Chir Scand 1965;129:500-508.
Hamilton HW, Crawford JS, Gardiner JH, et al. Venous thrombosis in patients with fracture of the upper end of the femur: a phlebographic study of the effect of prophylactic anticoagulation. J Bone Joint Surg Br 1970;52:268-289
Smith MD, Bressler EL, Lonstein JE, et al. Deep venous thrombosis and pulmonary embolism after major reconstructive operations on the spine. J Bone Joint Surg Am 1994;76:980-985.
Dearborn JT, Hu SS, Tribus CB, et al. Thromboembolic complications after major thoracolumbar spine surgery. Spine 1999;24:1471-1476.
Chang JY, Kostuik J, Sieber A. Complications of spinal fusion in treatment of adult spinal deformity [abstract]. Spine J 2002;2:55S.
Catre MG. Anticoagulation in spinal surgery: a critical review of the literature. Can J Surg 1997;40:413-419.
West JL, Anderson LD. Incidence of deep vein thrombosis in major adult spinal surgery. Spine 1992;17:S254-S257.
Flinn WR, Sandager GP, Cerullo LJ, et al. Duplex venous scanning for the prospective surveillance of perioperative venous thrombosis. Arch Surg 1989; 124:901-905.
Ferree BA, Stern PJ, Jolson RS, et al. Deep venous thrombosis after spinal surgery. Spine 1993;18:315-319.
Ferree BA, Wright AM. Deep venous thrombosis following posterior lumbar spinal surgery. Spine 1993;18:1079-1082.
Ferree BA. Deep venous thrombosis following lumbar laminotomy and laminectomy. Orthopedics 1994;17:35-38.
Flinn WR, Sandager GP, Silva MB, et al. Prospective surveillance for perioperative venous thrombosis: experience in 2643 patients. Arch Surg 1996; 131:472-480.
Nelson LD, Montgomery SP, Dameron TB, et al. Deep vein thrombosis in lumbar spinal fusion: a prospective study of antiembolic and pneumatic compression stockings. J South Orthop Assoc 1996;5:181-184.
Rokito SE, Schwartz MC, Neuwirth MG. Deep vein thrombosis after major reconstructive spinal surgery. Spine 1996;21:853-859.
Wood KB, Kos PB, Abnet JK, et al. Prevention of deep-vein thrombosis after major spinal surgery a comparison study of external devices. J Spinal Disord 1997;10:209-214.
Geerts WH, Code KI, Jay RM, et al. A prospective study of venous thromboembolism after major trauma. N Engl J Med 1994;331:1601-1606.
Meissner MH. Deep venous thrombosis in the trauma patient. Semin Vasc Surg 1998;11:274-282.
Rogers FB. Venous thromboembolism in trauma patients: a review. Surgery 2001;130:1-12.
Rogers FB, Cipolle MD, Velmahos G, et al. Practice management guidelines for the prevention of venous thromboembolism in trauma patients: the EAST Practice Management Guidelines Work Group. J Trauma 2002; 53:142-164.
O'Malley KF, Ross SE. Pulmonary embolism in major trauma patients. J Trauma 1990;30:748-750.
Elliott CG, Dudney TM, Egger M, et al. Calf-thigh sequential pneumatic compression compared with plantar venous pneumatic compression to prevent deep-vein thrombosis after non-lower extremity trauma. J Trauma 1999;47:25-32.
Huk M, Lynsky D, O'Callaghan T, et al. Compliance of sequential compression device for deep vein thrombosis prophylaxis in the adult trauma patient: surgical intensive care unit vs. intermediate care [abstract]. Crit Care Med 1998;26(suppl):A47.
Geerts WH, Jay RM, Code KI, et al. A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma. N Engl J Med 1996;335:701-707.
Knudson MM, Morabito D, Paiement GD, et al. Use of low molecular weight heparin in preventing thromboembolism in trauma patients. J Trauma 1996;41:446-459.
Cohn SM, Moller BA, Feinstein AJ, et al. Prospective trial of low-molecular-weight heparin versus unfractionated heparin in moderately injured patients. Vasc Surg 1999;33:219-223.
Upchurch GR, Demling RH, Davies J, et al. Efficacy of subcutaneous heparin in prevention of venous thromboembolic events in trauma patients. Am Surg 1995;61:749-755.
Acosta JA, Yang JC, Winchell RJ, et al. Lethal injuries and time to death in a level I trauma center. J Am Coll Surg 1998;186:528-533.
Meissner MH, Chandler WL, Elliott JS. Venous thromboembolism in trauma: a local manifestation of systemic hypercoagulability? J Trauma 2003; 54:224-231.
Velmahos GC, Kern J, Chan LS, et al. Prevention of venous thromboembolism after injury: an evidence-based report: Part II. Analysis of risk factors and evaluation of the role of vena caval filters. J Trauma 2000;49:140-144.
Velmahos GC, Kern J, Chan LS, et al. Prevention of venous thromboembolism after injury: an evidence-based report: Part I. Analysis of risk factors and evaluation of the role of vena caval filters. J Trauma 2000;49:132-139.
Devlin JW, Pettita A, Shepard AD, et al. Cost-effectiveness of enoxaparin versus low-dose heparin for prophylaxis against venous thrombosis after major trauma. Pharmacotherapy 1998;18:1335-1342.
Shorr AF, Ramage AS. Enoxaparin for thromboprophylaxis after major trauma: potential cost implications. Crit Care Med 2001;29:1659-1665.
Stover MD, Morgan SJ, Boisse MJ, et al. Prospective comparison of contrast-enhanced computed tomography versus magnetic resonance venography in the detection of occult deep pelvic vein thrombosis in patients with pelvic and acetabular fractures. J Orthop Trauma 2002;16:613-621.
Khansarinia S, Dennis JW, Veldenz HC, et al. Prophylactic Greenfield filter placement in selected high-risk traumam patients. J Vasc Surg 1995;22:231-236.
Wade WE, Chisholm MA. Deep venous thrombosis prophylaxis in trauma: cost analysis. Blood Coag Fibrinolysis 2000;11:101-106.
Selby R, Geerts WH. Venous thromboembolism prophylaxis after trauma: dollars and sense. Crit Care Med 2001;29:1839-1840.
Burns GA, Cohn SM, Frumento RJ, et al. Prospective ultrasound evaluation of venous thrombosis in high-risk trauma patients. J Trauma 1993; 35:405-408.
Brasel KJ, Borgstrom DC, Weigelt JA. Cost-effective prevention of pulmonary embolus in high-risk trauma patients. J Trauma 1997;42:456-462.
Rogers FB, Shackford SR, Wilson J, et al. Prophylactic vena cava filter insertion in severly injured trauma patients: indications and preliminary results. J Trauma 1993;35:637-641
Sing RF, Cicci CK, Smith CH, et al. Bedside insertion of inferior vena cava filters in the intensive care unit. J Trauma 1999;47:1104-1107.
Carlin AM, Tyburski JG, Wilson RF, et al. Prophylactic and therapeutic inferior vena cava filters to prevent pulmonary emboli in trauma patients. Arch Surg 2002;137:521-527.
McMurty AL, Owings JT, Anderson JT, et al. Increased use of prophylactic vena cava filters in trauma patients failed to decrease overall incidence of pulmonary embolism. J Am Coll Surg 1999;189:314-320.
Spain DA, Richardson JD, Polk HC, et al. Venous thromboembolism in the high risk trauma patient: do risks justify aggressive screening and prophylaxis? J Trauma 1997;42:463-469.
Pasquale M, Fabian TC. Development atEAHCoPMG: practice management guidelines for trauma from the Eastern Association for the Surgery of Trauma. J Trauma 1998;44:941-957.
Fernández-Pavón A, Martinez F, Cabañas L y col. Profilaxis en la Enfermedad trombólica venosa en el paciente politraumatizado. Rev Iberoamer Trombo Hemostasia 1999;12(2):77-81.
Gunduz S, Ogur E, Mohur H, et al. Deep vein thrombosis in spinal cord injured patients. Paraplegia 1993;31:606-610.
Deep K, Jigajinni MV, McLean AN, et al. Prophylaxis of thromboembolism in spinal injuries: results of enoxaparin used in 276 patients. Spinal Cord 2001; 39:88-91.
Spinal Cord Injury Thromboprophylaxis Investigators. Prevention of venous thromboembolism in the rehabilitation phase after spinal cord injury: prophylaxis with low-dose heparin or enoxaparin. J Trauma 2003;54:1111-1115.
Chen D, Apple DF, Hudson LM, et al. Medical complications during acute rehabilitation following spinal cord injury: current experience of the Model Systems. Arch Phys Med Rehabil 1999;80:1397-1401.
Ball PA. Critical care of spinal cord injury. Spine 2001;26(suppl):S27-S30.
Kanis JA. Heparin in the treatment of pulmonary thromboembolism. Thromb Diath Haemorrh 1974;32: 519-527.
Hull RD, Raskob GE, Rosenbloom D, et al. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med 1990;322:1260-1264.
Harrison L, Johnston M, Massicotte MP, et al. Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Ann Intern Med 1997; 126:133-136
Crowther MA, Ginsberg JB, Kearon C, et al. A randomized trial comparing 5-mg and 10-mg warfarin loading doses. Arch Intern Med 1999;159:46-48.
Kovacs MJ, Rodger M, Anderson DR, et al. Comparison of 10-mg and 5-mg warfarin initiation nomograms together with low-molecular-weight heparin for outpatient treatment of acute venous thromboembolism: a randomized, double-blind, controlled trial. Ann Intern Med 2003;138:714-719.
MacRae S, Ginsberg J. Initial treatment of venous thromboembolism Circulation 2004;110(suppl l):3-9.
Gallus A, Jackaman J, Tillett J, et al. Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism. Lancet 1986; 2:1293-1296
Hull RD, Raskob GE, Hirsh J, et al. Continuous intravenous heparin compared with intermitent subcut_neos heparin in the initial treatment of proximal vein thrombosis. N Eng J Med 1986;315:1109-1114.
Spinler SA, Inverso SM, Cohen M, et al. Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obeseand patients with severe renal impairment: analysis from ESSENCE and TIMI 11b studies. Am Heart J 2003;146:33-41.
Hull R, Delmore T, Genton E, et al. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Engl J Med 1979; 301:855-858.
Research Committee of the British Thoracic Society. Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Lancet 1992;340:873-876.
Schulman S, Rhedin AS, Lindmarker P, et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism: Duration of Anticoagulation Trial Study Group. N Engl J Med 1995;332:1661-1665.
Levine MN, Hirsh J, Gent M, et al. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost 1995;74:606-611.
Hull R, Delmore T, Carter C, et al. Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. N Engl J Med 1982;306:189-194.
Kearon C. Long term management of patients after thromboembolism. Circulation 2004;110(suppl I):10-18.
Lensing AW, Prins MH, Davidson BL, et al. Treatment of deep venous thrombosis with low-molecular-weight heparins: a meta-analysis. Arch Intern Med 1995;155:601-607.
Dolovich LR, Ginsberg JS, Douketis JD, et al. A metaanalysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch Intern Med 2000;160:181-188.
The Columbus Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med 1997; 337:657-662.
Koopman MM, Prandoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home: the Tasman Study Group. N Engl J Med 1996;334:682-687.
Harrison L, McGinnis J, Crowther M, et al. Assessment of outpatient treatment of deep-vein thrombosis with lowmolecular-weight heparin. Arch Intern Med 1998;158:2001-2003.
Merli G, Spiro TE, Olsson CG, et al. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Ann Intern Med 2001;134:191-202.
The Rembrandt investigators: Treatment of proximal deep vein trombosis with a novel syntetic compound (SR901071/ORG31540) with pure antifactor Xa activity. A phase II evaluation. Circulation 2000;102:2726 - 2731.
The Mattisse investigators: Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Eng J Med 2003;349:1695-1702.
Schulman S, Wahlander K, Lundstrom T, et al. Secondary prevention of venous thromboembolism with oral direct thrombin inhibitor ximelagatran. N Eng J Med 2003;349:1713-1722.
Goldhaber SZ, Meyerovitz MF, Green D, et al. Randomized controlled trial of tissue plasminogen activator in proximal deep venous thrombosis. Am J Med 1990; 88:235-240.
Lensing AW, Hirsh J. Rationale and results of thrombolytic therapy for deep vein thrombosis. In: Bernstein EF, ed. Vascular diagnosis. 4th ed. St. Louis, MO: Mosby, 1994;875-879.
Ouriel K, Gray B, Clair DG, et al. Complications associated with the use of urokinase and recombinant tissue plasminogen activator for catheter-directed peripheral arterial and venous thrombolysis. J Vasc Interv Radiol 2000;11:295-298.
Winter C, Weber H, Loeprecht H. Surgical treatment of iliofemoral vein thrombosis technical aspects: possible secondary interventions. Int Angiol 1989; 8:188-193.
Lansing AM, Davis WM. Five-year follow-up study of iliofemoral venous thrombectomy. Ann Surg 1968;168:620-628.
Bush R, Lin P, Bates J, et al. Pharmacomechanical thrombectomy for treatment of syntomatic lower extremity deep venous thrombosis: Safety and feasibility study. J Vasc Surgery 2004;40(5):965-970.
Decousus H, Leizorovicz A, Parent F, et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. N Engl J Med 1998;338:409-416.
Hann C, Streiff M. The role of vena caval filters in management of venous thromboembolism. Blood reviews 2004.
Hull R, Hirsh J, Jay R, et al. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med 1982; 307:1676-1681.
Schulman S, Granqvist S, Holmstrom M, et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism: The Duration of Anticoagulation Trial Study Group. N Engl J Med 1997;336:393-398.
Kearon C, Gent M, Hirsh J, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999;340:901-907.
Agnelli G, Prandoni P, Santamaria MG, et al. Three months versus one year of ora anticoagulant therapy for idiopathic deep venous thrombosis. N Engl J Med 2001;345:165-169.
Ridker PM, Goldhaber SZ, Danielson E, et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 2003;348:1425-1434.
Alpert JS, Smith R, Carlson J, et al. Mortality in patients treated for pulmonary embolism. JAMA 1976;236:1477-1480.
Hull R, Pineo GF, Mah A, et al. A randomised trial evaluating long-term low-molecular-weight heparin therapy for three months vs. intravenous heparin followed by warfarin sodium in patients with current cancer [abstract]. Thromb Haemost 2003;(suppl):P137a.
Kearon C, Ginsberg JS, Kovacs MJ, et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 2003;349:631-639.
Van Den Belt AG, Sanson BJ, Simioni P, et al. Recurrence of venous thromboembolism in patients with familial thrombophilia. Arch Intern Med 1997; 157:2227-2232.
Crowther MA, Kelton JG. Congenital thrombophilic states associated with venous thrombosis: a qualitative overview and proposed classification system. Ann Intern Med 2003;138:128-134.
Simioni P, Prandoni P, Lensing AW, et al. The risk of recurrent venous thromboembolism in patients with an Arg506-_ Gln mutation in the gene for factor V (factor V Leiden). N Engl J Med 1997;336:399-403.
Kyrle PA, Minar E, Hirschl M, et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med 2000;343:457-462
Khamashta MA, Cuadrado MJ, Mujic F, et al. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995; 332:993-997.
Crowthwe M, Wisloff F. Evidence base treatment of the antiphospholipid s_ndrome. II Optimal anticoagulant therapy for trombosis. Thrombosis research 2005;115:3-8.
Douketis JD, Kearon C, Bates S, et al. Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. JAMA 1998;279:458-462.
Hull RD, Raskob GE, Brant RF, et al. Low-molecular weight heparin vs heparin in the treatment of patients with pulmonary embolism: American-Canadian Thrombosis Study Group. Arch Intern Med 2000;160:229-236.
Simonneau G, Sors H, Charbonnier B, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. N Engl J Med 1997;337:663-669.
Anderson DR, Levine MN. Thrombolytic therapy for the treatment of acute pulmonary embolism. Can Med Assoc J 1992;146:1317-1324.
Meyer G, Brenot F, Pacouret G, et al. Subcutaneous low-molecular-weight heparin fragmin versus intravenous unfractionated heparin in the treatment of acute non massive pulmonary embolism: an open randomized pilot study. Thromb Haemost 1995;74:1432-1435.
Heit JA, Silverstein MD, Mohr DN, et al. Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study. Arch Intern Med 1999;159:445-453.
Agnelli G, Prandoni P, Becattini C, et al. Extended oral anticoagulant therapy after a first episode of pulmonary embolism. Ann Intern Med 2003;139:19-25.
Marder VJ. The use of thrombolytic agents: choice of patient, drug administration, laboratory monitoring. Ann Intern Med 1979;90:802-808.
Goldhaber SZ, Kessler CM, Heit J, et al. Randomised controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism. Lancet 1988;2:293-298.
Goldhaber SZ, Haire WD, Feldstein ML, et al. Alteplase versus heparin in acute pulmonary embolism: randomized trial assessing right-ventricular function and pulmonary perfusion. Lancet 1993;341:507-511.
Meneveau N, Schiele F, Vuillemenot A, et al. Streptokinase vs alteplase in massive pulmonary embolism: a randomized trial assessing right heart haemodynamics and pulmonary vascular obstruction. Eur Heart J 1997;18:1141-1148.
Tebbe U, Graf A, Kamke W, et al. Hemodynamic effects of double bolus reteplase versus alteplase infusion in massive pulmonary embolism. Am Heart J 1999;138:39-44.
Sharma GV, Burleson VA, Sasahara AA. Effect of thrombo lytic therapy on pulmonary-capillary blood volume in patients with pulmonary embolism. N Engl J Med 1980;303:842-845.
Cella G, Palla A, Sasahara AA. Controversies of different regimens of thrombolytic therapy in acute pulmonary embolism. Semin Thromb Haemost 1987;13:163-170.
Lopez Borrasca A, Arocha-Pichango CL, Campo Guerra C, et al. Enciclopedia Iberoamericana de Hematolog_a1992;Vol III:709-712.
Gray HH, Morgan JM, Paneth M, et al. Pulmonary embolectomy for acute massive pulmonary embolism: an analysis of 71 cases. Br Heart J 1988;60:196-200.
Clarke DB, Abrams LD. Pulmonary embolectomy: a 25 year experience. J Thorac Cardiovasc Surg 1986;92:442-445.
NOTA:Toda la información que se brinda en este artículo es de carácter investigativo y con fines académicos y de actualización para estudiantes y profesionales de la salud. En ningún caso es de carácter general ni sustituye el asesoramiento de un médico. Ante cualquier duda que pueda tener sobre su estado de salud, consulte con su médico o especialista.
Instituto de Medicina Tropical - Facultad de Medicina - Universidad Central de Venezuela.
Elaborado por el Centro de Análisis de Imágenes Biomédicas Computarizadas CAIBCO, caibco@ucv.ve
Este portal ha sido desarrollado gracias al apoyo del Fonacit
